Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial - PubMed
3 days ago
- #Clinical Trial
- #CDK4/6 Inhibitors
- #Breast Cancer
- The SONIA trial compared first-line vs second-line use of CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive, ERBB2-negative advanced breast cancer (ABC).
- No significant difference in overall survival (OS) was found between first-line (47.9 months) and second-line (48.1 months) CDK4/6i use (HR 0.91, P = 0.24).
- A post hoc subgroup analysis suggested an OS benefit with first-line CDK4/6i in premenopausal patients (HR 0.53) but not in postmenopausal patients (HR 1.00).
- First-line CDK4/6i use was associated with more grade 3 or higher adverse events (3400 vs 2242 in second-line).
- The trial concluded that first-line CDK4/6i did not improve OS compared to second-line use but increased treatment-related toxic effects.